The content on this site is intended for healthcare professionals only
Dr Javier Cortes speaks to ecancer in an online interview for the virtual BGICC 2021 meeting about updates in managing patients with HER2-positive breast cancer.
Dr Cortes gives updates on newly approved drugs that are improving outcomes, results from recent trials and changes in best practice.
Dr Cortes closes by giving his advice for treating these patients based on recent developments.
ESMO 2024: Highlights and analysis
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
Neo-adjuvant therapy for different cancers in the Philippines
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Novel antibody-drug conjugates (ADCs) technologies for management of mBC
The role of lymph nodes in stage 3 lung cancer
The role of multidisciplinary tumour board in managing stage 3 lung cancer
T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1
Systemic anti-cancer performance matrix
